InvestorsHub Logo
Followers 36
Posts 1466
Boards Moderated 0
Alias Born 11/12/2013

Re: None

Wednesday, 07/23/2014 6:23:54 PM

Wednesday, July 23, 2014 6:23:54 PM

Post# of 402172
If I may digress for a moment, I was just reading the PUMA story and it really got my heart to racing. Their cancer drug, neratinib, met its main goal in a late stage cancer trial for 1 indication, breast cancer, and the company added about $5B to its mkt cap in 1 day. Additionally, their drug was used in conjunction with another drug, Adjuvant. According to the company:

"Patients in the trial were treated with neratinib after adjuvant treatment with cancer drug trastuzumab in women with early-stage HER2-positive breast cancer.

Adjuvant treatment with the drug showed a statistically significant improvement in disease-free survival of 33 percent versus patients on placebo, according to trial data.

Adjuvant treatment, or additional treatment, is given after the primary treatment."

Puma, which doesn't have a drug on the market, will have to pay Pfizer double-digit royalties and Puma will be responsible for on-going clinical trial expenses. Puma also has about $195M in cash.

I don't think CTIX is similarly situated to Puma, I think CTIX is much, much better situated than Puma. Here's a link for story:

http://news.yahoo.com/puma-says-cancer-drug-meets-trial-goal-shares-220151726--finance.html?soc_src=mediacontentstory

Puma's 7-22 S/P= $59.03 Puma's 7-23 S/P=$233.43 Puma mkt cap=$7B
$7B mkt cap for CTIX=$66 for shares outstanding
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News